

DRIVE **AB** RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

May 2016



Remember: Clicking the coloured links will take you to more information!

Don't miss a beat - DRIVE-AB is on **Twitter!** Follow us at [@DRIVE_AB](#).

It's easier than ever for you to get involved! Just go to our website and click "**Stakeholder Engagement**" to find out all you need to know about getting involved with the project!

Or, fill out our **Expression of Interest Form** for stakeholders to let us know exactly how you or your organization would like to engage with the project. Please share this newsletter with other interested stakeholders as well!

DRIVE-AB Conference: Stimulating innovation, sustainable use and global access to antibiotics



2 June 2016

DRIVE-AB is organizing a **high-level conference** to bring together policy makers, regulatory and public health experts, and economists to identify and evaluate reward models that are feasible, practical and can be implemented globally. It is expected to stimulate a dialogue among international decision-makers on the implementation of R&D incentive policies which will help to inform DRIVE-AB's final recommendations in 2017. **A preliminary programme is available online. Online registration is now up and running.** If you wish to attend, please contact our Communications Officer Victoria Wells at vwells@bsac.org.uk.

DRIVE-AB Midterm Progress Featured at ECCMID



Poster summarizing DRIVE-AB progress to date developed for the European Congress on Clinical Microbiology and Infectious Diseases, April 2016 - Click to read an overview of DRIVE-AB's midterm progress.

DRIVE-AB WP1A, 'Responsible use of antibiotics, new and old', presents preliminary results at ECCMID 2016 - See the results for yourself below!

Work Package 1A had one oral presentation and four posters (details below) at ECCMID this year. These presented preliminary findings on quality and quantity indicators and metrics of antibiotic use in inpatient and outpatient settings. These findings were also discussed in

a **DRIVE-AB Train-the-Trainer workshop, "Defining and implementing responsible antibiotic use"**, for senior members of the European medical antibiotic stewardship community.

1. **Metrics for quantifying antimicrobial use in a hospital setting: results from a systematic review** (poster)
2. **Quantity metrics assessing antibiotic use in the outpatient setting: a global consensus procedure** (poster)
3. **Variation in indicators of antibiotic use among and within different settings: a systematic review** (poster)
4. **Quality indicators assessing antibiotic use in the outpatient setting: a systematic literature review followed by a consensus procedure** (poster)
5. **Quality indicators of antibiotic use in the inpatient setting: a global consensus procedure** (slide set)

DRIVE-AB featured at ECCMID Pipeline Corner and Pipeline Talk

ESCMID hosted a special event at ECCMID this year that featured the contributions of SMEs to the antibiotic R&D pipelines. Ursula Theuretzbacher, co-leader of Work Package 3B, organised the event and led the session, which gave an overview of the R&D programmes that are driving innovation in this critical space. European, US and Indian companies that presented their programs were well received.

What have we been up to?



DRIVE-AB co-hosted a symposium at the International Congress on Infectious Diseases in Hyderabad, India, 2-5 March 2016

On 5 March, 2016, DRIVE-AB co-hosted a symposium at the International Congress on Infectious Diseases in Hyderabad, India, titled "New and recently approved antibiotics: Challenges and opportunities". DRIVE-AB participant and Work Package 1C co-lead Ramanan Laxminarayan also chaired a session titled, "Antibiotic resistance: National actions contribute to a global solution. For more information about this meeting, please see the [meeting website](#).



DRIVE-AB featured at Gordon Research Conference on New Antibacterial Discovery & Development

The conference, held on 13-18 March, 2016, in Tuscany brought together highly experienced leaders in antibacterial drug discovery and development together with young investigators to discuss novel strategies for achieving potent and safe antibacterial drugs against the most difficult-to-treat organisms. Ursula Theuretzbacher presented DRIVE-AB and moderated a session on Learning from Clinical Experience with Novel Targets. A wealth of stakeholder feedback to DRIVE-AB's work on new economic models provided valuable insight into the challenges of antibiotic R&D from a broad range of perspectives.



Stefan Peterson
appointed Chief of Health
at UNICEF in New York

[Click here](#) to find out more.



DRIVE-AB's Ramanan Laxminarayan and John Rex involved in the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) and latest report



BEAM Alliance is DRIVE-AB's newest Associate Partner

[See our website](#) to find out more.

DRIVE-AB develops policy brief for political meetings

The consortium has developed a **policy brief, "The necessity for greater antibiotic innovation"**, for use at upcoming political meetings, including that hosted by the Global Antibiotic Research and Development (GARD) Partnership and the upcoming World Health Assembly (23-28 May) and the UN General Assembly (13-26 September).

Project updates by work package

Work Package 1

WP1A: Responsible use of antibiotics, new and old

In addition to their presentations at ECCMID, the team is also conducting interviews with partner hospitals, which is part of their study on barriers to responsible antibiotic use in inpatients. They are also administering a survey on the definition of responsible use, which is scheduled to close at the end of May 2016. The first case study has been finalized and will serve as the format framework for the following three. For more detailed information on the group's progress, please see WP1A's [stakeholder engagement webpage](#).

WP1B: Setting, communicating and revising public health priorities

The team has completed a systematic review to determine the clinical impact of antimicrobial

resistance and is finalising a data review of multidrug-resistant organism (MDRO) data. They are also working on progressing their mathematical model of within-hospital spread of MDROs to model global spread. This complex progression is expected to be completed in August 2016, and the final mathematical model is expected to be released in December 2016. For more detailed information on the group's progress, please see WP1B's [stakeholder engagement webpage](#).

WP1C: Antibiotic Evaluation

The group has completed a compilation of a list of 8 case studies including public health priorities and is in the process of developing a set of Health Technology Assessment case studies. Over the next few months, the team will be finalizing a paper providing a framework for valuing antibiotics. For more detailed information on the group's progress, please see WP1C's [stakeholder engagement webpage](#).

Work Package 2

WP2: Creation and testing of new economic models

The team has completed a report titled, "[Identified risks and bottlenecks to antibiotics innovation](#)". Moving forward, the group plans to continue work on selecting and refining models, designing simulations, evaluating the impact of market transitions on prescribing volumes, and laying the groundwork for the eventual implementation plan. This team will host a stakeholder meeting following the [DRIVE-AB Conference](#) on 3 June 2016 in Amsterdam. At this meeting, the group will share DRIVE-AB's preliminary technical analysis of their most promising reward models, identify implementation challenges and knowledge gaps and develop a roadmap for the remaining 18 months of the project. For more detailed information on the group's progress, please see WP2's [stakeholder engagement webpage](#).

Work Package 3

WP3A: Project management and governance

Along with ongoing project monitoring and management activities, the team has been supporting WP3B in the planning of the DRIVE-AB conference in June and has been holding monthly scientific forums for DRIVE-AB participants. The group has also had significant success in increasing industry involvement in the project. Over the next few months, WP3A plans to organise with IMI the midterm project review meeting (an internal process within IMI during which the progress of the project is evaluated by external experts).

For more detailed information on the group's progress, please see WP3A's [webpage](#).

WP3B: Stakeholder platform and external communication

In addition to the development of the [poster at ECCMID](#) and the [policy brief](#), the team have been very busy planning and organizing the DRIVE-AB conference for policy-makers which will be held in Amsterdam on 2 June 2016. They also facilitated Work Package 1A's [Train-the-Trainer event](#) on defining and implementing responsible use in Europe. In addition to organising meetings, the group continues to manage project communications both internally and externally by monitoring and updating the website, the Twitter account and the newsletters, planning other upcoming meetings, and managing potential and novel stakeholders. For more detailed information on the group's progress, please see WP3B's [webpage](#).

Other news

Don't forget about the two-sided information card offering a full, summarized [overview of the DRIVE-AB project](#). These information cards are available for download on the



DRIVE-AB RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

www.drive-ab.eu #DRIVE_AB

Driving reinvestment in R&D for antibiotics and advocating their responsible use

DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and is composed of 16 public and 7 private partners from 12 countries.

What is the problem?

Antibiotic resistance is a global public health threat that is getting worse every year. It is estimated that antibacterial drug resistance costs the EU at least EUR 1.5 billion and 25 000 lives each year. The development of new drugs to treat resistant infections is falling behind; new economic models that offer incentives for the discovery and development of new antibiotics and reconcile these with responsible antibiotic use and access are long overdue.



What we plan to do

- Define standards and metrics for responsible antibiotic use
- Estimate the current and future impact of antibiotic resistance on societies in order to determine future public health needs
- Quantify the value of new antibiotics
- Create, test and validate new economic models to incentivise the discovery and development of new antibiotics
- Recommend to governments and policy-makers new economic models that stimulate innovation, responsible use and global access of novel antibiotics to meet public health needs



DRIVE-AB website, along with other resources.

Please share these information cards with any colleagues or friends that may be interested in the project - the more stakeholders we have, the more robust and relevant our outputs will be!

Should you wish to receive more detailed information, nominate another stakeholder or update us on your activities relevant to the project, please contact **Victoria Wells**, DRIVE-AB Communications Officer.

[Edit your subscription](#) | [Unsubscribe](#)